Dear Colleagues,

On behalf of the Editor-in-Chief, Prof. Dr. Samuel C. Mok, we wish to acknowledge our reviewers who so generously offer their time to review the papers submitted to Cancers by presenting an award to the reviewers who have demonstrated their dedication, professionalism, and timeliness in reviewing manuscripts for Cancers.

What are the pre-requisites to be eligible for this award?

• All of the reviewers for Cancers in 2023 will be automatically included.

Selection Criteria:

• Number of review reports;
• The quality and timeliness of review reports.

What will the winners receive?

The Committee will select sixteen dedicated reviewers to receive Recognition Awards for Manuscript Review and four persons to receive the Outstanding Award for Excellence in Manuscript Review.

The Recognition Awards for Manuscript Review will consist of the following:

• An opportunity to publish a paper free of charge in Cancers after peer review before the end of December 2024;
• An electronic certificate.

The Outstanding Award for Excellence in Manuscript Review will consist of the following:

• CHF 500;
• An opportunity to publish a paper free of charge in Cancers after peer review before the end of December 2024;
• An electronic certificate.

When will the winners be announced?

• The winners will be announced in March 2024 on the journal website.

How can I make myself eligible?

• If you have not yet reviewed papers for Cancers, but would like to do so, you can register as a reviewer at the following link: https://susy.mdpi.com/volunteer/profile/edit.

Kind regards,
Cancers Editorial Office

Dear Colleagues,

The journal Cancers is inviting applications for the 2023 Best PhD Thesis Award. This prize will be awarded to two PhD students or recently qualified PhD students who have produced a highly anticipated thesis with great academic potential. The applications will be assessed by an evaluation committee led by the Editor-in-Chief, Prof. Dr. Samuel C. Mok.

Eligibility and Requirements

• The candidate must be a PhD student or recently qualified PhD who has produced a highly anticipated thesis with great academic potential;
• The PhD thesis must be their original work;
• The PhD thesis must be defended between 1 September 2022 and 31 August 2023.

Required Application Documents

• An executive summary of the PhD thesis in English of around 3000 words;
• A letter from the PhD supervisor recommending the candidate for consideration for this award;
• The candidate’s CV, including a list of publications connected with the thesis;
• An electronic copy of the PhD thesis;
• A scanned copy of the PhD diploma (or certificate of studying at a school or research institute as a PhD student going to graduate or participate in graduation thesis defenses).

Selection Criteria

• Quality of resume and publications;
• Relevance of the candidate and research description;
• Novelty of the candidate’s PhD thesis;
• Strength of the recommendation letter;
• Anticipated academic potential;
• Originality and impact of the research.

Prizes

• Bonus (CHF 800);
• Certificate;
• Offer to publish one paper free of charge in Cancers after peer review before the end of 202

The application deadline is 31 October 2023. The winners will be announced on the Cancers website by the end of December 2023.

Cancers Editorial Office

Dear Colleagues,
We are pleased to announce that Cancers is now inviting nominations for the Cancers 2023 Young Investigator Award. This prize will be given to one young investigator in recognition of their excellence in the field of oncology. All nominations will be assessed by an Award Evaluation Committee led by the Editor-in-Chief, Prof. Dr. Samuel C. Mok.

The Prizes:
– 2000 CHF (Swiss francs);
– Option to publish one paper free of charge in Cancers after peer review before the end of 2024;
– An electronic certificate.

Eligibility and Requirements:
– Must have received their PhD no more than 10 years prior to 31 December 2023;
– Must have produced ground-breaking research and made a significant contribution to the advancement of oncology;
– Candidates must be nominated by senior scientists.

List of Documents for Nomination:
– Detailed Curriculum Vitae, including an updated publication list and a list of the researcher’s own research grants;
– Scanned copy of doctorate certificate;
– Signed nomination letters from two established senior scientists.

Schedule:
Open for nomination: 3 March 2023
Nomination deadline: 30 September 2023
Winner announcement: 30 November 2023

How to Submit Nominations?
The nominations must be submitted online.

Contact
Ms. Louisa Zhou
Marketing Specialist
Email: [email protected]

Cancers Editorial Office

Dear Colleagues,

We are pleased to announce that Cancers will be granting the Travel Award to two junior scientists. The applications will be assessed by an Evaluation Committee consisting of senior scholars from the Cancers Editorial Board.

This award provides financial support for the winners to attend an international conference in the field of oncology to be held in 2023, in order to hold a presentation, present a poster, or both.

Candidate Requirements:

– Postdoctoral fellows or PhD students.
– Plans to attend an international conference in 2023 (oral presentation or poster).

Required Application Documents:

– Information of the conference the applicant is planning to attend and the abstract that will be submitted.
– Curriculum Vitae and list of publications.
– Justification letter describing the focus of the research (max. 800 words).
– Letter of recommendation from the supervisor, research director, or department head, which also confirms the applicant’s status as a postdoctoral fellow/PhD student.

The winners (two awardees) will each be awarded CHF 800 and a certificate. 

Please submit your applications for the Cancers 2023 Travel Award online by 31 May 2023. Prizes will be awarded at the end of June 2023 and announced on the Cancers website.

Dear Colleagues,

We are pleased to announce the “Cancers 2022 Best Paper Award” for research and review articles published in Cancers from 1 January 2022 to 31 December 2022. Two reviews and two research articles will receive an award each. The papers will be selected after a thorough evaluation by the journal Award Committee led by the Editor-in-Chief, Prof. Dr. Samuel C. Mok.

Eligibility for the Award:
– Papers published in Cancers from 1 January 2022 to 31 December 2022;
– Open to all career levels;
– Both regular and Special Issue submissions will be considered.

Selection Criteria:
The papers will be selected by the journal Award Committee according to the following criteria:
– Scientific merit and broad impact;
– Originality of the research objectives and/or the ideas presented;
– Creativity of the study design or uniqueness of the approaches and concepts;
– Clarity of presentation;
– Citations and downloads.

The Prize:
Two review awards and two research article awards will each receive CHF 500, an electronic certificate and a chance to publish a paper free of charge in Cancers in 2024 after peer review.

The winners will be announced on the journal website in March 2024.

Kind regards,
Cancers Editorial Office

Dear Colleagues,

We are pleased to announce the winners of the Cancers 2021 Best Paper Award. All papers published from 1 January 2021 to 31 December 2021 in Cancers were considered for the award. After a thorough evaluation of the originality and significance of the papers, citations, and downloads, four winners were selected.

Two Reviews:
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
By Alessandro Rizzo et al.
Cancers 2021, 13(3), 558; doi: 10.3390/cancers13030558

STING Agonists as Cancer Therapeutics
By Afsaneh Amouzegar and Jason J. Luke et al.
Cancers 2021, 13(11), 2695; doi: 10.3390/cancers13112695

Two Articles:
LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
By Christian Sordo-Bahamonde, Ana P. González-Rodríguez and Segundo Gonzalez et al.
Cancers 2021, 13(9), 2112; doi: 10.3390/cancers13092112

The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab
By Matteo Bauckneht et al.
Cancers 2021, 13(13), 3117; doi: 10.3390/cancers13133117

Each winner will receive CHF 500 and a chance to publish a paper free of charge in Cancers in 2023 after peer review.

Please join us in congratulating the winners of the Cancers 2021 Best Paper Award. We would also like to take this opportunity to thank all of our authors for your continued support of Cancers.

Kind regards,
Cancers Editorial Office

Dear Colleagues,

We are pleased to announce that the following referees (in alphabetical order by name) have been selected to receive the “Cancers 2022 Outstanding Reviewer Award”. The Journal Editorial Board and Editorial Team would like to acknowledge the time and effort dedicated by the reviewers to checking the manuscripts submitted to Cancers. It is due to their efforts that the high quality of the journal and quick turnaround have been maintained.

The Outstanding Awards for Excellence in Manuscript Reviews:
(CHF 500, an electronic certificate, and the opportunity to publish a paper free of charge in Cancers after peer review before the end of December 2023):

The Recognition Awards for Manuscript Reviews:
(An electronic certificate, and the opportunity to publish a paper free of charge in Cancers after peer review before the end of December 2023):

Kind regards,
Cancers Editorial Office

Dear Colleagues,

As the Editor-in-Chief of Cancers, it is my great pleasure to announce the winners of the Cancers 2022 PhD Thesis Award. This award is for two PhD students or recently qualified PhDs who have produced a highly anticipated thesis with great academic potential.

The award has been granted to:

“Uncovering Novel Prognostic and Predictive Epigenetic Biomarkers in Malignant Testicular Germ Cell Tumors” By João Pedro da Silva Machado Lobo, University of Porto, Portugal

“Metastatic Recurrence in Colorectal Cancer Arises from Residual EMP1+ Cells” By Adrià Cañellas Socias, University of Barcelona, Spain

Each winner will receive CHF 800, a certificate, and a chance to publish a paper free of charge after peer review in Cancers in 2023.

On behalf of the evaluation committee, I would like to congratulate the winners on their accomplishments. We would also like to take this opportunity to thank all the applicants for submitting their exceptional theses and the Award Committee for voting and helping with this award.

Prof. Dr. Samuel C. Mok
Editor-in-Chief, Cancers

Dear Colleagues,
We are pleased to announce that the winners of the Cancers 2022 Young Investigator Award are Dr. Ashleigh Poh and Dr. Miranda Fidler-Benaoudia.

Dr. Ashleigh Poh is an early career post-doctoral research fellow at the Olivia Newton-John Cancer Research Institute, Australia. She received her PhD in 2017. Her work focuses on therapeutic approaches to re-invigorate anti-tumour immunity by reprogramming immunosuppressive myeloid cells towards an immune-stimulatory endotype. Dr. Ashleigh Poh’s research was the first to identify a tumour cell-extrinsic role for the myeloid-specific kinase HCK in solid cancers by enhancing the polarization of immunosuppressive ‘alternatively activated’ macrophages. These discoveries have leveraged major industry partnerships to develop small molecule HCK inhibitors for clinical use. Dr. Ashleigh Poh independently secured >$1.5m in competitive funding as a principal investigator. Her ability to generate highquality research is also evidenced by her winning 20 awards and giving 30 invited presentations.

Dr. Miranda Fidler-Benaoudia is a Cancer Epidemiologist/Research Scientist at Alberta Health Services, Canada and an Adjunct Assistant Professor at the University of Calgary, Canada. Her research focuses on understanding the magnitude of the late affects among survivors of childhood, adolescent, and young adult cancer and developing tertiary prevention interventions to mitigate cancer- and treatment-related sequalae. She is additionally interested in sub-populations, such as indigenous peoples, and she undertakes research comprehensively to decribe cancer indicators nationally, regionally, and globally. Prior to her current positions, she received her PhD at the University of Birmingham, UK, in 2015 and completed a postdoctoral fellowship at the International Agency for Research on Cancer, France, from 2015 to 2018. She has made significant contributions to the field of oncology as a young investigator, with 44 peer-reviewed publications, 4 invited oral presentations, and 34 oral/poster presentations, as well as numerous memberships on editorial boards and national committees.

Please join us in congratulating Dr. Ashleigh Poh and Dr. Miranda Fidler-Benaoudia for their outstanding achievements.

As the awardees, each of them will receive an honorarium of CHF 2000, an electronic certificate, an offer to publish a paper free of charge before the end of 2023 in Cancers after peer review.

We would like to thank all those who nominated a candidate from various fields of study for their participation and all the Award Committee Members for their evaluation of the many excellent nominees.

Cancers 2022 Young Investigator Evaluation Committee

Dear Colleagues,

As the Editor-in-Chief of Cancers, I am pleased to announce the winners of the Cancers 2022 Travel Awards.

The awards have been granted to Diego de Miguel Perez, a postdoctoral fellow from the Icahn School of Medicine at Mount Sinai, and Luigi Russo, a postdoctoral fellow from the Italian Institute of Technology (IIT).

With so many high-quality applicants, the evaluation process and final decision were challenging. We would like to thank all of the applicants for submitting their diverse and fascinating range of research topics. On behalf of the Assessment Committee, I congratulate the winners on their accomplishments.

Prof. Dr. Samuel C. Mok
Editor-in-Chief, Cancers

Dear Colleagues,

We are pleased to announce the winners of Cancers 2021 Outstanding Reviewer Awards. The Cancers Editorial Board and Editorial Team would like to gratefully acknowledge the time and energy dedicated by reviewers in checking the manuscripts submitted to Cancers. It is due to their efforts that the high quality of the journal and quick turnaround are maintained.

The winners will each receive CHF 500, an electronic certificate, and a chance to publish a paper free of charge in Cancers after peer review in 2022:

Dr. Antonio G. Solimando
Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy

Dr. Chenghui Li
Department of Pharmacy Practice, University of Arkansas for Medical Sciences, Little Rock, USA

Dr. Joaquim Carreras
Department of Pathology, Tokai University, Isehara, Japan

Dr. Pierfrancesco Franco
Department of Oncology - Radiation Oncology, University of Turin School of Medicine, Turin, Italy

Dr. Laurentiu Pop
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, USA

Kind regards,
Prof. Dr. Samuel C. Mok
Editor-in-Chief, Cancers

Dear colleagues,

As the Editor-in-Chief of Cancers, it is my great pleasure to announce the winner of the Cancers 2021 Ph.D. Thesis Award. This prize has been awarded to a Ph.D. student who has produced a highly anticipated academic potential thesis.

The award has been granted to:

“Immunological Basis of Abscopal Antitumor Responses Induced by Combination of Distinct Radiotherapy Fractionation Schedules with Autologous Tumor Vaccines and Checkpoint Inhibition” by Dr. rer. nat. Michael Rückert, Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen, Germany.

Dr. rer. nat. Michael Rückert will be awarded 800 CHF and a certificate, and a chance to publish one paper free of charge in Cancers during the period 2021–2022.

On behalf of the evaluation committee, I would like to congratulate Dr. rer. nat. Michael Rückert on his accomplishments. We would also like to take this opportunity to thank all the nominated research groups of the above exceptional thesis for their contributions to Cancers, and thank the Award Committee for voting for and helping with this award.

Prof. Dr. Samuel Mok.
Editor-in-Chief, Cancers

Dear Colleagues,

The editorial team would like to congratulate the winners of the Cancers 2019 Best Paper Awards, who were chosen by a Selection Committee chaired by the Editor-in-Chief, Prof. Dr. Samuel C. Mok. Following a review process by the Evaluation Committee, four winners were selected. The recipients of the “Cancers 2019 Best Paper Awards” are as follows:

Article:

CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid (doi: 10.3390/cancers11050674)
By: Lynsey M. Whilding, Leena Halim, Benjamin Draper, Ana C. Parente-Pereira, Tomasz Zabinski, David Marc Davies and John Maher
Cancers 2019, 11(5), 674.

Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma (doi: 10.3390/cancers11040450)
By: Saeed Daneshmandi, Barbara Wegiel and Pankaj Seth
Cancers 2019, 11(4), 450.

Review：

Gut Microbiota and Cancer: From Pathogenesis to Therapy (doi: 10.3390/cancers11010038)
By: Silvia Vivarelli, Rossella Salemi, Saverio Candido, Luca Falzone, Maria Santagati, Stefania Stefani, Francesco Torino, Giuseppe Luigi Banna, Giuseppe Tonini and Massimo Libra
Cancers 2019, 11(1), 38.

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review (doi: 10.3390/cancers11071033)
By: Gabrielle Planes-Laine, Philippe Rochigneux, François Bertucci, Anne-Sophie Chrétien, Patrice Viens, Renaud Sabatier and Anthony Gonçalves
Cancers 2019, 11(7), 1033.

Each winner (corresponding author) will receive 500 CHF and a chance to publish a paper free of charge in Cancers in 2021 after the normal peer-review procedure.

Please join us in congratulating the winners of Cancers 2019 Best Paper Awards. We would also like to take this opportunity to thank all of our authors for their continued support of Cancers.

Dear Colleagues,

The editorial team would like to congratulate the winners of the Cancers 2020 Best Paper Award, who were chosen by a selection committee chaired by the Editor-in-Chief, Prof. Dr. Samuel C. Mok. Following a review process by the Award Evaluation Committee, four winners were selected.

Article:
Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems
By Ranjit Manchanda, Li Sun, Shreeya Patel, Olivia Evans, Janneke Wilschut, Ana Carolina De Freitas Lopes, Faiza Gaba, Adam Brentnall, Stephen Duffy, Bin Cui, Patricia Coelho De Soarez, Zakir Husain, John Hopper, Zia Sadique, Asima Mukhopadhyay, Li Yang, Johannes Berkhof and Rosa Legood
Cancers 2020, 12(7), 1929; doi: 10.3390/cancers12071929

Single-Cell Transcriptomic Analysis of Tumor-Derived Fibroblasts and Normal Tissue-Resident Fibroblasts Reveals Fibroblast Heterogeneity in Breast Cancer
By Aimy Sebastian, Nicholas R. Hum, Kelly A. Martin, Sean F. Gilmore, Ivana Peran, Stephen W. Byers, Elizabeth K. Wheeler, Matthew A. Coleman and Gabriela G. Loots
Cancers 2020, 12(5), 1307; doi: 10.3390/cancers12051307

Review:
Ferroptosis in Cancer Cell Biology
By Christina M. Bebber, Fabienne Müller, Laura Prieto Clemente, Josephine Weber and Silvia von Karstedt
Cancers 2020, 12(1), 164; doi: 10.3390/cancers12010164

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
By Raju K. Vaddepally, Prakash Kharel, Ramesh Pandey, Rohan Garje and Abhinav B. Chandra
Cancers 2020, 12(3), 738; doi: 10.3390/cancers12030738

Each winner (corresponding author) will receive CHF 500, a chance to publish a paper free of charge in Cancers in 2022 after the normal peer-review procedure, and an electronic certificate.

Please join us in congratulating the winners of the Cancers 2020 Best Paper Award. We would also like to take this opportunity to thank all of our authors for your continued support of Cancers.

Kind regards,
Cancers Editorial Office

Dear Colleagues,

We are pleased to announce the winners of the Cancers 2020 Outstanding Reviewer Awards. The Cancers Editorial Board and Editorial Team would like to gratefully acknowledge the time and energy dedicated by reviewers in checking the manuscripts submitted to Cancers. It is due to their efforts that the high quality of the journal and quick turnaround are maintained.

Dr. Pedro Miguel Rodrigues, Biodonostia Health Research Institute, Spain

Dr. Hua-Sheng Chiu, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, USA

They will receive the following:
– An electronic certificate;
– 1000 Swiss francs (CHF);
– An offer to publish a paper free of charge in Cancers after peer review before the end of 2021.

Kind regards,

Dear Colleagues,

We are pleased to announce that the winners of the Cancers 2020 Young Investigator Awards are Dr. Lukas Bunse and Dr. Ylenia Perone.

Dr. Bunse is a postdoctoral researcher and a team leader at the Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Germany. Dr. Bunse’s research interests are in oncoimmunology, transgenic cell therapy, and vaccine development. He received his MD (Dr. med) in 2016 and his Ph.D. (Dr. rer. nat.) in 2020 and has an outstanding publication record, comprising 23 publications in peer-reviewed international journals and 2 international patents. Dr. Bunse’s Scopus Scientific Citations number is 1390 and his Hirsch index is 12. He is clearly a rising star in the field of neuro-oncology. As a single applicant, Dr. Bunse has secured funding of more than EUR 1.4 million since 2018.

Dr. Perone MD, Ph.D., is a Clinical Research Fellow in Medical Oncology at the Imperial College London, UK. Dr. Perone’s research interests range from clinical research and clinical trials to basic scientific research in the endocrine-related cancer field. Dr. Perone was awarded a prestigious Cancer Research UK (CRUK) Ph.D. Fellowship at Imperial College London and received her Ph.D. degree in 2020. Her research aimed to understand the interplay between epigenetics and lipid metabolism in endocrine therapy-resistant nuclear receptor-positive cancer. She is clearly a rising star in the field with an outstanding record of achievement for a young investigator at this stage of her career comprising ten publications in peer-reviewed international journals, two invited oral presentations at International Conferences, and twelve Awards and Prizes.

This is an outstanding achievement in today’s competitive environment. Please join us in congratulating Dr. Bunse and Dr. Perone for their outstanding achievements.

As the awardee, Dr. Bunse and Dr. Perone will receive an honorarium of 2000 CHF, an offer to publish a paper free of charge before 2021 in Cancers after peer review, and an electronic certificate.

We would like to thank all the nominators and nominees from various fields of study for their participation and all the Award Committee Members for their evaluation of the many excellent nominations.

The following four nominees will be given a 15% discount on a paper to be published in Cancers in 2021.

• Arutha Kulasinghe, Queensland University of Technology, Australia
• John Charles Rotondo, University of Ferrara, Italy
• Mohamed Saad, Monash University, Australia

Prof. Dr. Samuel C. Mok
Editor-in-Chief, Cancers

Dear Colleagues,

We are pleased to announce that the winner of the 2018 Cancers Young Investigator Award is Dr. Sarah McClelland. Dr. McClelland will receive an award of 2000 Swiss Francs, an offer to publish a paper free of charge without a fixed deadline in Cancers, and an engraved plaque.

Dr. Sarah McClelland is a lecturer in Molecular Oncology at the Barts Cancer Institute, Queen Mary University of London. Dr. McClelland received her Ph.D. degree in 2003 and worked as a postdoctoral research fellow from 2003 to 2013. In 2013 she established her laboratory at the Barts Cancer Institute, Queen Mary University of London. Here, her research aims to understand causes of chromosome mis-segregation in the context of ovarian and pancreatic cancer, and also to characterise fundamental mechanisms controlling genetic stability. Her laboratory recently discovered that individual human chromosomes behave non-randomly during error-prone mitosis, which has important implications for understanding the widespread chromosome changes in cancer. Dr. McClelland’s track record of achievements is impressive for a young investigator at this stage of her career.

We would like to thank all the applicants in various fields of study for their participation and the Award Committee members for reviewing the numerous high-quality applications received.

Prof. Dr. Samuel C. Mok
Cancers Editorial Office
Editor-in-Chief

Dear Colleagues,

As Editor-in-Chief of the open access journal Cancers, it is my pleasure to announce that the winner of the 2017 Cancers Travel Award is Dr. Cecilia Leung, Ph.D. Dr. Leung is a postdoctoral researcher in Prof. Giulio Draetta’s laboratory at the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

On behalf of Cancers, she will be supported with 1000 Swiss Francs towards travel expenses to attend the American Association for Cancer Research (AACR) Annual Meeting 2017 to be held at Washington, D.C., USA.

Dr. Leung’s current research focuses on epigenetic regulation of pancreatic cancer progression. Using pooled shRNA epigenome library, she and her colleagues performed an in vivo loss-of-function screen and identified COMPASS-like complexes, which have specific H3K4 methyltransferase activity, to be key oncogenic drivers of pancreatic cancer. Dr. Leung has co-authored ten publications of which three are as first author, many in high profile journals (such as Nature Communications, Cancer Research and Clinical Cancer Research). She has also already been the recipient of numerous awards.

Prof. Samuel C. Mok
Editor-in-Chief